Health-Related Quality of Life With Nivolumab Plus Chemotherapy Versus Chemotherapy in Patients With Advanced Gastric/Gastroesophageal Junction Cancer or Esophageal Adenocarcinoma From CheckMate 649

Simple item page
dc.contributor.authorMoehler, Markus
dc.contributor.authorXiao, Hong
dc.contributor.authorBlum, Steven I.
dc.contributor.authorElimova, Elena
dc.contributor.authorCella, David
dc.contributor.authorShitara, Kohei
dc.contributor.authorAjani, Jaffer A.
dc.contributor.authorJanjigian, Yelena Y.
dc.contributor.authorGarrido, Marcelo
dc.contributor.authorShen, Lin
dc.contributor.authorYamaguchi, Kensei
dc.contributor.authorLiu, Tianshu
dc.contributor.authorSchenker, Michael
dc.contributor.authorKowalyszyn, Ruben
dc.contributor.authorBragagnoli, Arinilda Campos
dc.contributor.authorBruges, Ricardo
dc.contributor.authorMontesarchio, Vincenzo
dc.contributor.authorPazo-Cid, Roberto
dc.contributor.authorHunter, Shannon
dc.contributor.authorDavenport, Eric
dc.contributor.authorWang, Jinyi
dc.contributor.authorKondo, Kaoru
dc.contributor.authorLi, Mingshun
dc.contributor.authorWyrwicz, Lucjan
dc.date.accessioned2025-01-20T17:20:21Z
dc.date.available2025-01-20T17:20:21Z
dc.date.issued2023
dc.description.abstractPURPOSE In CheckMate 649, first-line nivolumab plus chemotherapy prolonged overall survival versus chemotherapy in patients with advanced/metastatic non-human epidermal growth factor receptor 2 (HER2)-positive gastric/gastroesophageal junction cancer (GC/GEJC) or esophageal adenocarcinoma (EAC). We present exploratory patient-reported outcomes (PROs).METHODS In patients (N = 1,581) concurrently randomly assigned 1:1 to nivolumab plus chemotherapy or chemotherapy and in those with tumor PD-L1 expression at a combined positive score (CPS) of >= 5, health-related quality of life (HRQoL) was assessed using the EQ-5D and Functional Assessment of Cancer Therapy-Gastric (FACT-Ga), which included the FACT-General (FACT-G) and Gastric Cancer subscale (GaCS). The FACT-G GP5 item assessed treatment-related symptom burden. Longitudinal changes in HRQoL were assessed using mixed models for repeated measures in the PRO analysis population (randomly assigned patients with baseline and >= 1 postbaseline assessments). Time to symptom or definitive deterioration analyses were also conducted.RESULTS In the PRO analysis population (n = 1,360), PRO questionnaire completion rates were mostly >80% during treatment. Patient-reported symptom burden was not increased with nivolumab plus chemotherapy versus chemotherapy. Mean improved changes from baseline were greater with nivolumab plus chemotherapy versus chemotherapy for FACT-Ga total, GaCS, and EQ-5D visual analog scale in patients with a CPS of >= 5; results were similar for the overall PRO analysis population. In CPS >= 5 and all randomly assigned populations, nivolumab plus chemotherapy reduced the risk of symptom deterioration versus chemotherapy, on the basis of FACT-Ga total score and GaCS; time to definitive deterioration was longer, and the risk of definitive deterioration in HRQoL was reduced with nivolumab plus chemotherapy across EQ-5D and most FACT-Ga measures (hazard ratio [95% CI] <1).CONCLUSION Compared with chemotherapy alone, first-line nivolumab plus chemotherapy showed stable or better on-treatment HRQoL in patients with advanced/metastatic non-HER2-positive GC/GEJC/EAC and also showed decreased risk of definitive HRQoL deterioration.
dc.description.funderAgilent Technologies company, Santa Clara - Bristol Myers Squibb
dc.fuente.origenWOS
dc.identifier.doi10.1200/JCO.23.00170
dc.identifier.eissn1527-7755
dc.identifier.issn0732-183X
dc.identifier.urihttps://doi.org/10.1200/JCO.23.00170
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/91425
dc.identifier.wosidWOS:001118796700015
dc.issue.numero35
dc.language.isoen
dc.pagina.final+
dc.pagina.inicio5388
dc.revistaJournal of clinical oncology
dc.rightsacceso restringido
dc.subject.ods03 Good Health and Well-being
dc.subject.odspa03 Salud y bienestar
dc.titleHealth-Related Quality of Life With Nivolumab Plus Chemotherapy Versus Chemotherapy in Patients With Advanced Gastric/Gastroesophageal Junction Cancer or Esophageal Adenocarcinoma From CheckMate 649
dc.typeartículo
dc.volumen41
sipa.indexWOS
sipa.trazabilidadWOS;2025-01-12
Files
Collections
Artículos de revistas